Posted by Michael Wonder on 17 Mar 2022
‘Keytruda reimbursement provides global standard care for Korean lung cancer patients’
17 March 2022 - MSD’s Keytruda (pembrolizumab) became reimbursable for the first-line treatment of non-small-cell lung cancer in March, enabling Korean patients to get Keytruda-based standard care.
MSD Korea held a press conference on Wednesday to share the implication of the anti-PD-1 immunotherapy Keytruda’s winning broader insurance coverage and the drug’s distinguished treatment benefit.
